[
1. Kankaria R, Sanina C, Gabr M, et al – „Extracardiac prothrombotic effects of COVID-19” – Cardiol Clin 2022, 40 (3) 277-39410.1016/j.ccl.2022.03.008896015635851457
]Search in Google Scholar
[
2. Jiménez D, Garcia-Sanchez A, Rali P, et al – „Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus disease 2019: a systematic review and meta analysis” – Chest 2021, 159, 1182-119610.1016/j.chest.2020.11.005767088933217420
]Search in Google Scholar
[
3. Bilaloglu S, Aphinyanaphongs Y, Jones S – „Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System” – JAMA 2020, 324 (8) 79910.1001/jama.2020.13372737250932702090
]Search in Google Scholar
[
4. Fauvel C, Weizman O, Trimaille A, et al – „Pulmonary embolism in COVID-19 patients: a French multicenter cohort Study” – Eur Heart 2020, 41: 3058-6810.1093/eurheartj/ehaa500752895232656565
]Search in Google Scholar
[
5. Klok F.A, Kruip M.J.H.A, van der Meer N.J.M, et al – „Incidence of thrombotic complications in critically ill ICU patients COVID-19” – Thromb Res 2020, 191, 145-14710.1016/j.thromres.2020.04.013714671432291094
]Search in Google Scholar
[
6. Siow I, Lee K.S, Zhang J.J.Y, et al – „Stroke as a Neurologic Complications of COVID-19: A Systematic Review and Meta Analysis of Incidence, Outcomes and Predictors”–J Stroke Cerebrovasc Dis 2021, 30, 10554910.1016/j.jstrokecerebrovasdis.2020.105549783412133341565
]Search in Google Scholar
[
7. Nannoni S, Rosa de Groot, Bell S – „Stroke in COVID- 19 a systematic review and meta analysis” – Int J Stroke 2021, 16 (2), 137-14710.1177/1747493020972922785957833103610
]Search in Google Scholar
[
8. Qureshi A.I, Baskett W.I, Huang W, et al – „Acute ischaemic Stroke and COVID-19: an analysis of 27676 patients” – Stroke 2021, 52, 905-91210.1161/STROKEAHA.120.031786790398233535779
]Search in Google Scholar
[
9. Perry R.J, Smith C.J, Roffe C, et al – „Characteristics and outcomes of COVID-19 associated Stroke: a UK multicenter case-control Study” – J Neurol Neurosurg Psychiatry 2021, 92, 24210.1136/jnnp-2020-32492733154179
]Search in Google Scholar
[
10. Majidi S, Fifi J.T, Ladner T.R, et al – „Emergent Large Vessel Occlusion Stroke During New York City’s COVID-19 Outbreak: Clinical Characteristics and Paraclinical Findings” – Stroke 2020, 51, 2656-266310.1161/STROKEAHA.120.030397743400432755349
]Search in Google Scholar
[
11. Libby P – „COVID-19, in the end of endothelial disease” – Eur Heart J 2020, 41, 3038-4910.1093/eurheartj/ehaa623747075332882706
]Search in Google Scholar
[
12. Lowenstein C.J, Solomon S.D – „Severe COVID-19 is a microvascular disease” – Circulation 2020, 142/1609-161110.1161/CIRCULATIONAHA.120.050354758065132877231
]Search in Google Scholar
[
13. Page E.M, Ariëns R.A.S – „Mechanisms of thrombosis and cardiovascular complications in COVID-19” – Thromb Res 2021, 200, 1-810.1016/j.thromres.2021.01.005781350433493983
]Search in Google Scholar
[
14. Connors J.M – „Thromboinflammation and hypercoagulability of COVID-19” – J Thromb Haemost 2020, 18, 155810.1111/jth.14849977092032302453
]Search in Google Scholar
[
15. Spyropoulos A.C – „Studying the coagulopathy of COVID-19” – Lancet 2022, 399, 118-2010.1016/S0140-6736(21)01906-1859818134800425
]Search in Google Scholar
[
16. Schulman S, Sholzberg M, Spyropoulos A.C, et al – „ISTH Guidelines for antithrombotic treatment in COVID- 19” – J Thromb Haemostasis 2022-DOI: 10,1111/JTH 1580810.1111/jth.15808
]Search in Google Scholar
[
17. Connors J.M, Brooks M.M, Sciurba F.C, et al – „Effect of antithrombotic therapy on clinical outcomes in outpatients with Clinically Stable Symptomatic COVID-19: the ACTIVE-4B” – JAMA 2021, 326, 1702-1712
]Search in Google Scholar
[
18. RECOVERY Collaborative Group – „Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label” – Lancet 2022, 399, 143-51
]Search in Google Scholar
[
19. Flam B, Wintzell U, Ludvigsson J, et al – „Direct oral anticoagulant use and risk of severe COVID-19” – J Intern Med 2021, 289, 411-1910.1111/joim.13205775356433258156
]Search in Google Scholar
[
20. Shen L, Qiu L, Liu D, et al – „The association of low molecular weight heparin use in hospital mortality among patients hospitalized with COVID-19” – Cardiovasc Drugs Ther 2021, 36, 113-12010.1007/s10557-020-07133-3777964833394360
]Search in Google Scholar
[
21. Sholzberg M, da Costa B.R, Tang G.H, et al – „Randomized trial of therapeutic heparin for COVID-19: a meta-analysis” – Res Pract Thromb Haemostasis 2021, 5:e1263810.1002/rth2.12638868187934977448
]Search in Google Scholar
[
22. Lawler P.R, Goligher E.C, Berger J.S, et al – „Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19” – New Engl J Med 2021, 385, 790-80210.1056/NEJMoa2105911836259434351721
]Search in Google Scholar
[
23. Meizlish M.L, Goshua G, Liu Y, et al – „Intermediate- dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score matched analysis” – Am J Haemat 2021, 96, 471-47910.1002/ajh.26102801358833476420
]Search in Google Scholar
[
24. Spyropoulos A.C, Goldin M, Giannis D, et al – „Efficacy and safety of therapeutic dose heparin vs standard prophylactic or intermediate-dose heparin for thromboprophylaxis in high-risk hospitalized patients with COVID-19” – JAMA Intern Med 2021, 181: 1612-1120
]Search in Google Scholar
[
25. Berger J.S, Kornblith L.Z, Gong M, et al – „Effect of P2Y12 inhibitors on survival free of organ support among noncritically ill hospitalized patients with COVID-19” – JAMA 2022, 327, 227-236
]Search in Google Scholar
[
26. Lopes R.D, Pedro Gabriel Melo de Barros, Furtado Remo H.M, et al – on behaf of the ACTION Coalition – „Therapeutic versus prophylactic anticoagulation for patients” Lancet 2021, 397: 2253-63
]Search in Google Scholar
[
27. Lemos A.B.C, do Espírito Santo D.A, Salvetti M.C, et al – „Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial” – Thromb Res 2020, 196, 359-36610.1016/j.thromres.2020.09.026750306932977137
]Search in Google Scholar
[
28. Goligher E.C, Bradbury C.A, McVerry B.J, et al – „Therapeutic anticoagulation with heparin in critically ill patients with COVID-19” – New Engl J Med 2021, 385, 777-78910.1056/NEJMoa2103417836259234351722
]Search in Google Scholar
[
29. Dogra S, Jain R, Cao M, et al – „Neurologic Stroke and anticoagulant in COVID-19” – J Stroke Cerebrovasc Des 2020, 2910.1016/j.jstrokecerebrovasdis.2020.104984724525432689588
]Search in Google Scholar
[
30. Reis S, Popp M, Schieber S, et al – „Anticoagulation in COVID-19 patients in COVID-19 an update systematic review and meta-analysis” – Trombo Rev 2022, 219, 40-4810.1016/j.thromres.2022.09.001945193636113402
]Search in Google Scholar
[
31. Giannis D, Allen S.L, Tsang J, et al – „Postdischarge tromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE Registy” – Blood 2021, 137, 2838-284710.1182/blood.2020010529803247433824972
]Search in Google Scholar
[
32. Ramacciotti E, Barile Agati L, Calderaro D, et al – „Rivaroxaban versus no anticoagulation for postdischarge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE), an open-label, multicentre, randomised, controlled trial” – Lancet 2022, 399, 50-5910.1016/S0140-6736(21)02392-8867388134921756
]Search in Google Scholar
